News

The new cancer treatment also attracts tumours directly. Tracy Robson and her research team at Queen’s, in collaboration with researchers at Almac Discovery, developed a new drug to

The research agreement, which was previously signed in March 2003, has been extended for another year. Accordingly, the term of the agreement will end in March 2012. As

Munshi is a co-founder and the former chief business officer of KYTHERA Biopharmaceuticals. Before KYTHERA, Munshi was the general manager of Amgen’s European Nephrology Business, with responsibility for

The ALN-VSP Phase I trial is designed to recruit patients with advanced solid tumors with liver involvement who have failed to respond to or have progressed after standard

Daxas (roflumilast) is an orally administered selective phosphodiesterase 4 (PDE4) enzyme inhibitor, which has been shown to inhibit COPD related inflammation with a novel mode of action. The

Livatag is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells. It was granted an orphan drug status in Europe and in the US. The

Each retail package of Sucanon contains 60 tablets and is the equivalent of a one-month patient supply. Pre-clinical and clinical studies of Sucanon showed that Sucanon and other

PRT062607 is a novel, oral Spleen Tyrosine Kinase (Syk)-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosis, and certain cancers,

FDA alleged in letters to drug companies that their products were ‘unapproved new drugs’ which can no longer be marketed legally in the US for safety problems associated